MedTrace Logo

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 723

Last updated 2026-05-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.

Conditions

  • Menstrual Migraine

Interventions

DRUG

Rimegepant

Rimegepant 75 mg ODT for 7 days

DRUG

Placebo Comparator

Matching placebo oral disintegrating tablets for 7 days

DRUG

Standard of Care

Standard of care for acute treatment as needed

DRUG

Rimegepant

Rimegepant 75 mg ODT for acute treatment as needed

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-11
Primary Completion
2026-11-29
Completion
2027-03-30
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Canada
  • China
  • Denmark
  • Germany
  • India
  • Italy
  • Japan
  • Mexico
  • Netherlands
  • Poland
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06641466 on ClinicalTrials.gov